Grace Koennecke

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”

ABI-201 aims to prevent dry AMD and other retinal disorders in patients.

The company announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes.

Ophthalmologist offers insights into the value of technology in diabetic retinopathy.

The funding will help further the glaucoma program alongside new board member Carol Gallagher.

The new formula will help relieve temporary symptoms caused by dryness of the eye.

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1).

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

Sonia H. Yoo, MD, a cornea, cataract, and refractive surgery specialist and a member of the planning committee for the EnVision Summit, highlights a session focused on the latest advancements in lens implant technologies, refractive procedures, and imaging innovations. The summit will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from preclinical to clinical phase of drug development.

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to needed resources.

The program will deliver a range of high-quality access and affordability services for retina specialists.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.

The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

The funding will support activities like formal pharmacology and toxicology testing.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists. She shared these thoughts at this year's AAO meeting held in Chicago, Illinois.

Glenn C. Yiu, MD, PhD, from the University of California David, shared insights from his presentation on suprachoroidal drug delivery in the real world at this year's AAO meeting held in Chicago, Illinois.

John Josephson, MD, from the Eye Specialists and Surgeons of Northern Virginia, shared insights on office-based surgeries and how it allows for the addition of new technologies and new procedures at this year's AAO meeting held in Chicago, Illinois.

Brian Francis, MD, from the Doheny Eye Institute and the UCLA Department of Ophthalmology, shared insights on MIGS techniques and the labs and didactic available while at this year's AAO meeting held in Chicago, Illinois.

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias.

Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.

With many benefits, AI technology does have the potential to change the way practices work in the coming years, but it may require additional advancements in terms of relieving physician burnout and driving organization.

The US gymnast has become an overnight sensation for competing with strabismus and coloboma at the 2024 Olympic Games in Paris.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.